Since dual silencing of FTs and GGTs has not shown deleterious effects in mice, combinatory therapy of FTIs and GGTIs or Dual Prenylation Inhibitors (DPIs) have been proposed for treating KRAS-mutated tumours. Here, KRAS is linked to neoplasm.